title: Integrated profiling of diffuse large B-cell lymphoma with 7q gain.
abstract: To characterize diffuse large B-cell lymphoma (DLBCL) with chromosome 7 gains, we combined clinical data with genomic, RNA and miRNA profiling. Gains were associated with age >60 years, female gender, a trend for higher complete response rate, lower death rate, and better overall survival in patients treated with R-CHOP. Lesions were inversely associated with bone marrow involvement and number of extra-nodal sites. Differentially expressed transcripts were enriched of genes belonging to specific pathways and miRNAs targets. MIR96, MIR182, MIR589, MIR25 were shown significantly up-regulated in 7q+ DLBCL by real-time PCR.
authors.affiliation: Laboratory of Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, via Vincenzo Vela 6, Bellinzona, Switzerland.
authors.forename: Ekaterina
authors.initials: E
authors.lastname: Chigrinova
authors.forename: Michael
authors.initials: M
authors.lastname: Mian
authors.forename: Yulei
authors.initials: Y
authors.lastname: Shen
authors.forename: Timothy C
authors.initials: TC
authors.lastname: Greiner
authors.forename: Wing C
authors.initials: WC
authors.lastname: Chan
authors.forename: Julie M
authors.initials: JM
authors.lastname: Vose
authors.forename: Giorgio
authors.initials: G
authors.lastname: Inghirami
authors.forename: Annalisa
authors.initials: A
authors.lastname: Chiappella
authors.forename: Luca
authors.initials: L
authors.lastname: Baldini
authors.forename: Maurilio
authors.initials: M
authors.lastname: Ponzoni
authors.forename: Andrés J M
authors.initials: AJ
authors.lastname: Ferreri
authors.forename: Silvia
authors.initials: S
authors.lastname: Franceschetti
authors.forename: Gianluca
authors.initials: G
authors.lastname: Gaidano
authors.forename: Alessandra
authors.initials: A
authors.lastname: Tucci
authors.forename: Fabio
authors.initials: F
authors.lastname: Facchetti
authors.forename: Thierry
authors.initials: T
authors.lastname: Lazure
authors.forename: Olivier
authors.initials: O
authors.lastname: Lambotte
authors.forename: Santiago
authors.initials: S
authors.lastname: Montes-Moreno
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Piris
authors.forename: Emanuele
authors.initials: E
authors.lastname: Zucca
authors.forename: Ivo
authors.initials: I
authors.lastname: Kwee
authors.forename: Francesco
authors.initials: F
authors.lastname: Bertoni
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D058674:Chromosome Duplication; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D020869:Gene Expression Profiling / Q000379:methods; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D035683:MicroRNAs / Q000235:genetics; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012334:RNA, Neoplasm / Q000235:genetics; D000069283:Rituximab; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D035683:MicroRNAs; D012334:RNA, Neoplasm; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone